In addition, the results of our susceptibility analysis showed that high FBN2 expression was associated with the better sensitivity of five chemotherapeutic agents in the treatment of BLCA, which may suggest that these chemotherapeutic agents were more suitable for BLCA patients with high FBN2 expression. This evidence concerns the gene FBN2 and bladder transitional cell carcinoma.